Galectin Therapeutics Inc (NASDAQ:GALT) price target upped to $1.00, released a report earlier today by Zacks Investment Research
- Updated: November 28, 2016
Boasting a price of $0.91, Galectin Therapeutics Inc (NASDAQ:GALT) traded 1.11% higher on the day. With the last stock price close down -37.27% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.03% over the date range. Galectin Therapeutics Inc has recorded a 50-day average of $0.83 and a two hundred day average of $1.43. Volume of trade was down over the average, with 0 shares of GALT changing hands under the typical 725,769
Stating a potential upside of 0.10%, Zacks Investment Research bumped up the target of Galectin Therapeutics Inc (NASDAQ:GALT) to $1.00
With a total market value of $0, Galectin Therapeutics Inc has with a one year low of $0.49 and a one year high of $3.05 .
A total of 3 equity analysts have released a research note on GALT. One equity analyst rating the company a strong buy, two equity analysts rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $8.33.
More About Galectin Therapeutics Inc (NASDAQ:GALT)
Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company's galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.